Protective effect of hydrogen sulfide on balloon injury-induced neointima hyperplasia in rat carotid arteries

被引:123
作者
Meng, Qing H.
Yang, Guangdong
Yang, Wei
Jiang, Bo
Wu, Lingyun
Wang, Rui
机构
[1] Lakehead Univ, Dept Biol, Thunder Bay, ON P7B 5E1, Canada
[2] Univ Saskatchewan, Dept Pathol & Lab Med, Saskatoon, SK, Canada
[3] Univ Saskatchewan, Dept Physiol, Saskatoon, SK, Canada
[4] Univ Saskatchewan, Dept Pharmacol, Saskatoon, SK S7N 0W0, Canada
基金
加拿大健康研究院;
关键词
D O I
10.2353/ajpath.2007.060939
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Endogenous hydrogen sulfide (H2S), generated from homocysteine metabolism mainly catalyzed by cystathionine gamma-lyase (CSE), possesses important functions in the cardiovascular system. in this study, we investigated the role of H,S during the pathogenesis of neointimal formation induced by balloon injury in rats. CSE mRNA levels were reduced by 86.5% at 1 week and 64.0% at 4 weeks after balloon injury compared with the uninjured controls. CSE activity was also correspondingly reduced. Endogenous production of H,S in the injured carotid artery was significantly inhibited at 1 week and 4 weeks after balloon injury. Treatment with NaHS (a donor of H,S) enhanced methacholine-induced vasorelaxation of balloon-injured artery. More importantly, treatment with NaHs significantly inhibited neointima formation (0.15 +/- 0.01 nun 2 versus 0.21 +/- 0.01 mm(2), P < 0.001) of the balloon-injured carotid arteries and reduced the intima/media ratio (1.05 +/- 0.07 versus 1.43 +/- 0.06, P < 0.001). A significant decrease in vascular smooth muscle cell proliferation was demonstrated by bromodeoxyuridine incorporation at day 7 after injury. In conclusion, CSE expression and H,S production are reduced during the development of balloon injury-induced neointimal hyperplasia, and treatment with NaHS significantly reduces neointimal lesion formation.
引用
收藏
页码:1406 / 1414
页数:9
相关论文
共 36 条
[1]   Hyperhomocysteinemia activates nuclear factor-κB in endothelial cells via oxidative stress [J].
Au-Yeung, KKW ;
Woo, CWH ;
Sung, FL ;
Yip, JCW ;
Siow, YL ;
O, K .
CIRCULATION RESEARCH, 2004, 94 (01) :28-36
[2]   Role of hyperhomocysteinemia in endothelial dysfunction and atherothrombotic disease [J].
Austin, RC ;
Lentz, SR ;
Werstuck, GH .
CELL DEATH AND DIFFERENTIATION, 2004, 11 (Suppl 1) :S56-S64
[3]   SMOOTH-MUSCLE CELL-MIGRATION AND MATRIX METALLOPROTEINASE EXPRESSION AFTER ARTERIAL INJURY IN THE RAT [J].
BENDECK, MP ;
ZEMPO, N ;
CLOWES, AW ;
GALARDY, RE ;
REIDY, MA .
CIRCULATION RESEARCH, 1994, 75 (03) :539-545
[4]   HETEROZYGOSITY FOR HOMOCYSTINURIA IN PREMATURE PERIPHERAL AND CEREBRAL OCCLUSIVE ARTERIAL-DISEASE [J].
BOERS, GHJ ;
SMALS, AGH ;
TRIJBELS, FJM ;
FOWLER, B ;
BAKKEREN, JAJM ;
SCHOONDERWALDT, HC ;
KLEIJER, WJ ;
KLOPPENBORG, PWC .
NEW ENGLAND JOURNAL OF MEDICINE, 1985, 313 (12) :709-715
[5]   Hydrogen sulfide-induced relaxation of resistance mesenteric artery beds of rats [J].
Cheng, YQ ;
Ndisang, JF ;
Tang, GH ;
Cao, K ;
Wang, R .
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2004, 287 (05) :H2316-H2323
[6]   Homocysteine determinants and the evidence to what extent homocysteine determines the risk of coronary heart disease [J].
De Bree, A ;
Verschuren, WMM ;
Kromhout, D ;
Kluijtmans, LAJ ;
Blom, HJ .
PHARMACOLOGICAL REVIEWS, 2002, 54 (04) :599-618
[7]   Hyperhomocysteinemia and its role in the development of atherosclerosis [J].
de Koning, ABL ;
Werstuck, GH ;
Zhou, J ;
Austin, RC .
CLINICAL BIOCHEMISTRY, 2003, 36 (06) :431-441
[8]   Homocyst(e)ine and cardiovascular disease: A critical review of the epidemiologic evidence [J].
Eikelboom, JW ;
Lonn, E ;
Genest, J ;
Hankey, G ;
Yusuf, S .
ANNALS OF INTERNAL MEDICINE, 1999, 131 (05) :363-375
[9]   Endogenous hydrogen sulfide regulation of myocardial injury induced by isoproterenol [J].
Geng, B ;
Chang, L ;
Pan, CS ;
Qi, YF ;
Zhao, J ;
Pang, YZ ;
Du, JB ;
Tang, CS .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2004, 318 (03) :756-763
[10]   Inhibition of vascular smooth muscle cell proliferation and neointimal formation in injured arteries by a novel, oral mitogen-activated protein kinase/extracellular signal-regulated kinase inhibitor [J].
Gennaro, G ;
Ménard, C ;
Michaud, SE ;
Deblois, D ;
Rivard, A .
CIRCULATION, 2004, 110 (21) :3367-3371